HTB homepage • Conference reports • Articles by subject • Subscribe April 2000 Contents Editorial Welcome to HIV Treatment Bulletin (incorporating DrFax) Treatment alerts St John’s Wort: message from Professor A Breckenridge, Chair, Committee on Safety of Medicines. Conference reports 7th Conference on Retroviruses and Opportunistic Infections (ROI), January 30-February 2 2000, San Francisco Paediatrics: children are not small (or miniature) adults HIV-positive women, pregnancy and newborns Flu-like symptoms of severe acute HIV infection develop after suspension of HAART Non-clade B virus: epidemiology, testing strategies and resistance Treatment strategies French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3 PK and drug interactions Interactions of St John’s Wort (Hypericum perforatum) preparations Important safety information for people taking St John’s Wort preparations Guidelines Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women Other news French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3 Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women (April 2000) French Health Authority approves enteric coated ddI U.S. FDA approves film-coated nelfinavir mesylate (Viracept™) St John’s Wort PDFs Volume 1 Number 1 April 2000 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
